We are a privately held pharmaceutical company focused on the development and commercialization of JATENZO®, our oral testosterone replacement product. JATENZO is a new FDA approved T-replacement therapy. It is the first FDA approved oral formulation of a testosterone prodrug, namely, testosterone undecanoate (TU).
Based on our clinical trial results, JATENZO restores circulating testosterone to normal levels and overcomes the safety challenges, such as liver toxicity, historically associated with oral androgen-replacement therapies.
Our investors are Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd.